Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes
Posted inCardiology news

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFpEF, highlighting the roles of inflammation and adipose metabolism.
Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER
Posted inCardiology Internal Medicine news

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populations characterized by high risk heterogeneity.
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
Posted inCardiology Nephrology news

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
Posted inCardiology Diabetes & Endocrinology news

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase inhibitor AT-001 showed consistent safety and efficacy across both sexes.
Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing
Posted inCardiology Diabetes & Endocrinology news

Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing

A landmark post-hoc analysis of the DPPOS and DaQing studies reveals that achieving prediabetes remission reduces the risk of cardiovascular death and heart failure hospitalization by approximately 50% over three decades, highlighting a profound legacy effect of early glycemic normalization.
M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status
Posted inCardiology news

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

The RESHAPE-HF2 trial reveals that mitral transcatheter edge-to-edge repair (M-TEER) significantly reduces cardiovascular risks and enhances health status across all baseline patient conditions, reinforcing its role as a key intervention for symptomatic heart failure and secondary mitral regurgitation.
Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia
Posted inCardiology Internal Medicine news

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomagnesemic patients may increase risks, highlighting the necessity of baseline-guided clinical intervention.